Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 9/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13967978 | 0.84 | SCN9A (0.56) | ADORA2ASCN9APDE10A | |
| SCHEMBL13836819 | 0.84 | KMT2A (0.49) | SCN9APDE10A | |
| SCHEMBL13837206 | 0.78 | MBNL1 (0.44) | ADORA2ASCN9ATACR3PIK3R1PIK3CA | |
| SCHEMBL28276494 | 0.78 | ADORA2A (0.60) | ADORA2ADPP4ADORA2BADORA1 | |
| SCHEMBL13837048 | 0.78 | MAPT (0.51) | ABCG2 | |
| SCHEMBL1989452 | 0.71 | BCHE (0.46) | ADORA2ATACR3PTGDR2 | |
| SCHEMBL4167700 | 0.71 | ADORA2A (0.39) | ADORA2ATACR3ADORA1 | |
| SCHEMBL13967979 | 0.70 | RAB9A (0.47) | — | |
| SCHEMBL13836924 | 0.70 | MEN1 (0.62) | ADORA2APIK3R1PIK3CA | |
| SCHEMBL2015255 | 0.69 | BCHE (0.44) | ADORA2APTGDR2ADORA2BADORA1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952192-B2 | Phosphorylated and branched dihydroxy-pentane-dione (DPD) analogs as quorum sensing inhibitors in bacteria | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2015-02-10 | — | — | US | disclosed |
| US-20120294900-A1 | Phosphorylated and Branched Dihydroxy-Pentane-Dione (DPD) Analogs as Quorum Sensing Inhibitors in Bacteria | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120294900-A1 | Phosphorylated and Branched Dihydroxy-Pentane-Dione (DPD) Analogs as Quorum Sensing Inhibitors in Bacteria | PGD, DUSP2, PGLS | ADORA2A 383/4885SCN9A 4688/4885TACR3 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.